BE820660A - Procede de detection d'antigenes ou d'anticorps - Google Patents

Procede de detection d'antigenes ou d'anticorps

Info

Publication number
BE820660A
BE820660A BE149173A BE149173A BE820660A BE 820660 A BE820660 A BE 820660A BE 149173 A BE149173 A BE 149173A BE 149173 A BE149173 A BE 149173A BE 820660 A BE820660 A BE 820660A
Authority
BE
Belgium
Prior art keywords
antigen
detection process
antibody detection
antibody
detection
Prior art date
Application number
BE149173A
Other languages
English (en)
Inventor
I Bornstein
A Kapsalis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BE820660A publication Critical patent/BE820660A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/819—Multifunctional antigen or antibody
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
BE149173A 1973-10-26 1974-10-03 Procede de detection d'antigenes ou d'anticorps BE820660A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/410,066 US3949064A (en) 1973-10-26 1973-10-26 Method of detecting antigens or antibodies

Publications (1)

Publication Number Publication Date
BE820660A true BE820660A (fr) 1975-02-03

Family

ID=23623067

Family Applications (1)

Application Number Title Priority Date Filing Date
BE149173A BE820660A (fr) 1973-10-26 1974-10-03 Procede de detection d'antigenes ou d'anticorps

Country Status (15)

Country Link
US (2) US3949064A (fr)
JP (1) JPS5762020B2 (fr)
AU (1) AU476619B2 (fr)
BE (1) BE820660A (fr)
BR (1) BR7408886A (fr)
CA (1) CA1036493A (fr)
DE (1) DE2450523C3 (fr)
ES (1) ES431413A1 (fr)
FR (1) FR2249334B1 (fr)
GB (1) GB1436934A (fr)
IL (1) IL45707A (fr)
LU (1) LU71027A1 (fr)
NL (1) NL7413552A (fr)
SE (1) SE7413484L (fr)
ZA (1) ZA746098B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172117A (en) * 1974-05-20 1979-10-23 Biotest-Serum-Institut Gmbh Method for the simultaneous measurement of antigens and their antibodies by solid-phase radioimmunoassay
US4225784A (en) * 1976-06-17 1980-09-30 Smith Kline Instruments, Inc. Covalently bound biological substances to plastic materials and use in radioassay
AT343822B (de) * 1976-08-20 1978-06-26 Immuno Ag Radioimmunologisches verfahren und einrichtung zur bestimmung von antigenen
JPS604422B2 (ja) * 1976-10-07 1985-02-04 持田製薬株式会社 抗原の定量方法
USRE34394E (en) * 1978-01-23 1993-09-28 Baxter Diagnostics Inc. Method and composition for double receptor, specific binding assays
JPS608745B2 (ja) * 1978-02-14 1985-03-05 三洋化成工業株式会社 免疫活性物質−つや消しガラス複合体，その製造法及び該複合体を含有してなる測定試薬
US4242322A (en) * 1978-06-07 1980-12-30 Electro-Nucleonics Laboratories, Inc. Methods and materials for detecting antigens and antibodies
US4393040A (en) * 1981-03-24 1983-07-12 Lopapa Institute, Inc. In-vitro diagnostic method for detection of acetylsalicylic acid ingestion
US4994373A (en) 1983-01-27 1991-02-19 Enzo Biochem, Inc. Method and structures employing chemically-labelled polynucleotide probes
DE3461093D1 (en) * 1983-07-21 1986-12-04 Scripps Clinic Res Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mrnas, receptors, methods and diagnostics using the same
US5242798A (en) * 1983-07-21 1993-09-07 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
JPH07119760B2 (ja) * 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション ミモトープを検出または決定する方法
US5182082A (en) * 1991-01-23 1993-01-26 Becton, Dickinson And Company Multiple aliquot device for distributing a liquid solution into a well
US6168956B1 (en) 1991-05-29 2001-01-02 Beckman Coulter, Inc. Multiple component chromatographic assay device
US5877028A (en) * 1991-05-29 1999-03-02 Smithkline Diagnostics, Inc. Immunochromatographic assay device
US5998220A (en) * 1991-05-29 1999-12-07 Beckman Coulter, Inc. Opposable-element assay devices, kits, and methods employing them
US5348867A (en) * 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US5698686A (en) * 1994-10-20 1997-12-16 Arch Development Corporation Yeast telomerase compositions
US5807552A (en) * 1995-08-04 1998-09-15 Board Of Regents, The University Of Texas System Compositions for conferring immunogenicity to a substance and uses thereof
AU727445B2 (en) * 1995-08-18 2000-12-14 Donald W Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
US20020034732A1 (en) * 1997-07-30 2002-03-21 Daniel J. Capon Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
CA2350911A1 (fr) 1998-11-16 2000-05-25 Board Of Regents, The University Of Texas System Induction de lymphocytes t specifiques du vih
US7060462B2 (en) * 2000-11-02 2006-06-13 National University Of Singapore AopB gene, protein,homologs, fragments and variants thereof, and their use for cell surface display
EP2292762A3 (fr) 2002-12-20 2012-12-12 Board of Regents, The University of Texas System Séquences d'espèces et de souches de Borrelia pathogène de type VMP
WO2005035556A2 (fr) * 2003-05-06 2005-04-21 Iguazu Biosciences Corp. Particules pseudo-virales du coronavirus du sras et methodes d'utilisation
CA2526690C (fr) 2003-05-23 2014-01-14 Board Of Regents The University Of Texas System Oligonucleoside phosphorothioate selectionnes de maniere combinatoire et a base structurelle et facteurs de transcription ap-1 ciblant un phosphorodithioate aptamere
CA2637598A1 (fr) 2006-01-18 2007-02-14 University Of Chicago Compositions et procedes se rapportant a des proteines de bacteries staphylococciques
EP2115002B1 (fr) 2007-02-02 2014-08-20 Baylor Research Institute Vaccins a base d'antigene cible au dcir exprime dans des cellules presentant un antigene
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
US7786267B2 (en) 2007-02-02 2010-08-31 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
JP2010519313A (ja) * 2007-02-23 2010-06-03 ベイラー リサーチ インスティテュート Ｃｌｅｃ−６を介したヒト抗原提示細胞の活性化
WO2008103953A2 (fr) * 2007-02-23 2008-08-28 Baylor Research Institute Activation de cellules humaines présentant un antigène par l'intermédiaire du récepteur ldl 1 oxydé de type lectine (lox-1) de cellules dendritiques
NZ710459A (en) 2007-02-23 2016-06-24 Baylor Res Inst Therapeutic applications of activation of human antigen-presenting cells through dectin-1
US9138470B2 (en) * 2007-11-02 2015-09-22 The Johns Hopkins University Multi-component L2 vaccine for prevention of human papilloma virus infection
EP2307048A4 (fr) 2008-07-16 2012-02-29 Baylor Res Inst Vaccin contre le vih basé sur un ciblage maximisé de gag et nef par rapport à des cellules dendritiques
WO2010042481A1 (fr) 2008-10-06 2010-04-15 University Of Chicago Compositions et procédés associés aux protéines bactériennes eap, emp, et/ou adsa
KR20170102039A (ko) 2009-04-03 2017-09-06 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
WO2011100508A2 (fr) 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Procédés et compositions liés à des fusions glycoprotéine-immunoglobuline
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
WO2012034067A1 (fr) 2010-09-09 2012-03-15 The University Of Chicago Procédés et compositions impliquant des antigènes staphylococciques protecteurs
WO2012058635A1 (fr) 2010-10-29 2012-05-03 Life Technologies Corporation Dérivés de biotine
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
NZ702285A (en) 2012-04-26 2016-07-29 Univ Chicago Staphylococcal coagulase antigens and methods of their use
BR112015006840A2 (pt) 2012-09-27 2017-11-21 Res Found Dev vírus chikungunya atenuado
EP2964254B1 (fr) 2013-03-07 2019-09-18 University of Maryland, Baltimore Potentiel immunothérapeutique de lipooligosaccharides/lipide a modifiés
EP3142691A4 (fr) 2014-05-16 2018-04-11 Baylor Research Institute Méthodes et compositions de traitement de maladies auto-immunes et inflammatoires
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
US11413336B2 (en) 2018-03-23 2022-08-16 Board Of Regents, The University Of Texas System Coccidioides antigens and methods of their use
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
CN113811547B (zh) 2019-03-27 2024-06-25 国家医疗保健研究所 具有cd40激活特性的重组蛋白
CN114787181A (zh) 2019-11-21 2022-07-22 Inserm(法国国家健康医学研究院) 用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法
WO2021178637A1 (fr) 2020-03-05 2021-09-10 Iowa State University Research Foundation, Inc. Compositions immunogènes et vaccinales dirigées contre le sars-cov-2
US20230183366A1 (en) 2020-05-13 2023-06-15 Inserm (Institut National De La Santé Et De La Recherch Médicale) Recombinant proteins with ox40 activating properties
WO2023144779A1 (fr) 2022-01-28 2023-08-03 Pfizer Inc. Variants d'antigène de coronavirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (fr) * 1967-05-23 1971-08-02 Pharmacia Ab
SE343210B (fr) * 1967-12-20 1972-03-06 Pharmacia Ab
US3646346A (en) * 1968-12-26 1972-02-29 Pharmacia Ab Antibody-coated tube system for radioimmunoassay
US3867517A (en) * 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies

Also Published As

Publication number Publication date
CA1036493A (fr) 1978-08-15
JPS5075095A (fr) 1975-06-20
USRE29955E (en) 1979-04-03
FR2249334B1 (fr) 1977-03-25
SE7413484L (fr) 1975-04-28
DE2450523C3 (de) 1978-06-22
US3949064A (en) 1976-04-06
DE2450523A1 (de) 1975-05-22
AU476619B2 (en) 1976-09-30
GB1436934A (en) 1976-05-26
AU7378774A (en) 1976-04-01
ZA746098B (en) 1975-11-26
LU71027A1 (fr) 1975-04-17
BR7408886A (pt) 1976-05-04
JPS5762020B2 (fr) 1982-12-27
ES431413A1 (es) 1976-10-16
FR2249334A1 (fr) 1975-05-23
IL45707A (en) 1977-01-31
NL7413552A (nl) 1975-04-29
IL45707A0 (en) 1974-11-29
DE2450523B2 (de) 1976-10-07

Similar Documents

Publication Publication Date Title
BE820660A (fr) Procede de detection d'antigenes ou d'anticorps
FR2274047A1 (fr) Nouveau procede de detection de la presence d'antigenes et d'anticorps
BE799417A (fr) Procede de direction et de determination d'haptenes,
BE764883A (fr) Procede de preparation d'hydrogenosilanes
RO63722A (fr) Procede de preparation de l'uree
BE795950A (fr) Procede de preparation d'amidosilanes
BE807706A (fr) Procede pour la preparation de cycloalcanones et/ou cycloalcanols
CH554319A (fr) Procede de preparation d'aryl-guanidines ortho-disubstituees.
FR2277891A1 (fr) Methode pour deceler par radio-immunometrie la presence d'anticorps de la blennorragie
BE786518A (fr) Procede de preparation d'oxa-bicyclo-alcenes
CH551437A (fr) Procede de preparation d'acides chromone-carboxyliques.
BE785344A (fr) Procede de preparation d'alcenyl-silanes
BE752499A (fr) Procede de preparation d'amines secondaires ou
BE786156A (fr) Procede de preparation de l'anhydride
BE806124A (fr) Procede de preparation d'hydrazones
BE831145A (fr) Procede de dosage immunologique utilisant un systeme heterologue d'anticorps ou d'antigenes
BE795902A (fr) Procede de preparation du diiodo-3,5 hydroxy-4benzonitrile et de l'iodo-3 hydroxy-4 nitro-5benzonitrile
BE802306A (fr) Procede de preparation d'agregats
BE806277A (fr) Procede pour la preparation de cycloalcanones et de cycloalcanols
BE774540A (fr) Procede de preparation de l'omega laurinolactame
BE809499A (fr) Procede et reactif pour le dosage de la creatinekinase
BE787014A (fr) Procede et reactif pour deceler la presence de l'antigene australien
RO62297A (fr) Procede de obtention d'un mixture proteique
BE779136R (fr) Procede de preparation d'acetoxy-1-methyl-3-butene-2-al-4
BE764210A (fr) Procede de preparation d'alcoyl-silanes